Status:

COMPLETED

Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis

Lead Sponsor:

University Health Network, Toronto

Collaborating Sponsors:

Grifols Therapeutics LLC

Conditions:

Myasthenia Gravid

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Immunomodulation is effective in treating patients with myasthenia gravis (MG), but prior studies have not adequately defined if plasma exchange (PLEX) in superior to intravenous immunoglobulin (IVIG)...

Eligibility Criteria

Inclusion

  • \>18 years old
  • diagnosis of moderate-severe MG (defined as a Quantitative Myasthenia Gravis Score QMGS \>10.5)
  • worsening weakness requiring a change in therapy judged by a neuromuscular expert

Exclusion

  • Worsening weakness secondary to concurrent medications (e.g. Aminoglycosides)
  • Worsening weakness secondary to infection
  • Change in corticosteroid dosage in the 2 weeks prior to screening
  • Other disorders causing weakness or fatigue
  • Known absolute IgA deficiency (risk of anaphylactic reaction to IVIG)
  • History of anaphylaxis or severe systemic response to IVIG or albumin
  • Pregnancy or breastfeeding
  • Active renal failure precluding volume of IVIG (risk of volume overload with IVIG) as judged by the investigators
  • Clinically significant cardiac disease precluding IVIG volume as judged by the investigators
  • Known hyperviscosity or hypercoaguable state (risk of stroke with IVIG)
  • Known coagulopathy with bleeding
  • On another current study medication or protocol within 4 weeks of screening
  • Patients with known refractory status to either IVIG or PLEX
  • Poorly controlled or severe hypertension (exacerbation by IVIG)
  • Patient refuses treatment with either IVIG or PLEX
  • Patient refuses follow-up with electrophysiological studies
  • Patient unable or unwilling to give informed consent

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2010

Estimated Enrollment :

87 Patients enrolled

Trial Details

Trial ID

NCT01179893

Start Date

March 1 2007

End Date

July 1 2010

Last Update

August 11 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Health Network

Toronto, Ontario, Canada, M5G 2C4

Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis | DecenTrialz